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ABSTRACT: In this study, we investigated the molecular
adhesion between the major constituents of cartilage
extracellular matrix, namely, the highly negatively charged
proteoglycan aggrecan and the type II/IX/XI ﬁbrillar collagen
network, in simulated physiological conditions. Colloidal force
spectroscopy was applied to measure the maximum adhesion
force and total adhesion energy between aggrecan end-
attached spherical tips (end radius R ≈ 2.5 μm) and trypsin-
treated cartilage disks with undamaged collagen networks.
Studies were carried out in various aqueous solutions to reveal
the physical factors that govern aggrecan−collagen adhesion.
Increasing both ionic strength and [Ca2+] signiﬁcantly
increased adhesion, highlighting the importance of electrostatic repulsion and Ca2+-mediated ion bridging eﬀects. In addition,
we probed how partial enzymatic degradation of the collagen network, which simulates osteoarthritic conditions, aﬀects the
aggrecan−collagen interactions. Interestingly, we found a signiﬁcant increase in aggrecan−collagen adhesion even when there
were no detectable changes at the macro- or microscales. It is hypothesized that the aggrecan−collagen adhesion, together with
aggrecan−aggrecan self-adhesion, works synergistically to determine the local molecular deformability and energy dissipation of
the cartilage matrix, in turn, aﬀecting its macroscopic tissue properties.
■ INTRODUCTION
The unique biomechanical properties of articular cartilage,
including compressive and shear resistance as well as shock
absorption, are directly governed by collective intra- and
intermolecular interactions between its extracellular matrix
(ECM) molecules. These interactions include electrostatics,
steric and entropic repulsion, and water−proteoglycan
molecular friction between the type II/IX/XI ﬁbrillar collagen
network and the enmeshed large proteoglycan aggrecan (Figure
1).1−4 In addition, it was reported that binding activities
between ECM molecules, while not directly contributing to
cartilage biomechanics, are critical in governing chondrocyte
activities and ECM assembly.5,6 For example, aggrecan
monomers bind to hyaluronan via its G1 domain to form
aggregates,7 stabilized by link proteins (Figure 1a),8 which
prevents aggrecan loss from cartilage ECM. Bindings between
aggrecan keratan sulfate glycosaminoglycan (KS-GAG) side
chains and collagen have been suggested to aﬀect the aggrecan
spatial distribution in vivo,9 and to protect collagen ﬁbrils from
proteolytic degradation.10 Speciﬁc bindings involving quantita-
tively minor matrix proteins and collagen, including decorin-
type II collagen, biglycan-type II collagen,11 cartilage
oligometric matrix protein (COMP)-type II collagen,12 and
biglycan-type VI collagen,13 regulate the ﬁbrillogenesis and
cross-linking of the collagen network. Bindings between these
proteins and cytokines, such as decorin and transforming
growth factor (TGF)-β, regulate cell signaling and mechano-
transduction.14,15 Besides these speciﬁc bindings, at physio-
logical density and molecular strain, aggrecan can undergo
nonspeciﬁc self-adhesion,16 despite the presence of strong
electrostatic repulsion between GAG side chains. This
aggrecan−aggrecan self-adhesion was suggested to be an
important factor contributing to the self-assembled hierarchical
architecture of cartilage ECM.16
While aggrecan self-adhesion has been investigated in
detail,16,17 there is a lack of understanding of direct, nonspeciﬁc
interactions between the two primary ECM constituents,
aggrecan and the ﬁbrillar collagen network. Knowledge of
aggrecan−collagen interactions could provide a critical step
forward in our understanding of the molecular basis of cartilage
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tissue function and the origins and characteristics of osteo-
arthritis. Toward this end, the objective of this study is to
investigate the mechanisms of aggrecan−collagen molecular
adhesion under simulated physiological conditions. We utilized
atomic force microscope (AFM)-based colloidal force spec-
troscopy to measure the adhesion between gold-coated
spherical colloid tips (R ≈ 2.5 μm) functionalized with end-
grafted aggrecan and the transversely isotropically aligned
collagen ﬁbrils of native bovine superﬁcial zone cartilage
surfaces in 0.15 M phosphate buﬀered saline (PBS; Figure 2a).
We studied the molecular origins of adhesion by comparing the
adhesions measured on the collagen specimen using the
aggrecan tip to those measured by a hydroxyl-terminated
spherical tip (Figure 2b,c), in which eﬀects like electrostatic
repulsion, hydrophobicity, and macromolecular entanglements
are eliminated. We quantiﬁed the inﬂuences of electrostatic
repulsion by changing the bath solution conditions, including
ionic strength (IS) and concentration of Ca2+. Furthermore, we
probed how osteoarthritic-like enzymatic degradation of
collagen aﬀects aggrecan−collagen adhesion in PBS (Figure
2a). These observations were interpreted in the context of
cartilage ECM macromolecular composition and structure to
provide insights into the tissue integrity of cartilage and the
characteristics of osteoarthritic degradation.
■ MATERIALS AND METHODS
Sample Preparation. Cartilage plugs were harvested from the
femoropatellar grooves of 1−2 week old bovine calves (Research ’87,
Hopkinton, MA) using a 6 mm dermal punch. Cartilage disks of ≈1.0
mm thickness were extracted from the plugs with intact superﬁcial
zone and surface. Disks were incubated for 12 h in phosphate buﬀered
saline (PBS, IS = 0.15 M, pH = 7.4) at 37 °C in the presence of 0.1
mg/mL bovine pancreatic trypsin (Sigma-Aldrich, St. Louis, MO) to
remove proteoglycans (PGs)18 without interrupting the macroscopic19
and microscopic20 structure or static tensile properties21 of the
collagen network. Tapping mode AFM images of trypsin-treated (PG-
depleted) disks showed the collagen network maintains its
nanostructure integrity after the trypsin treatment (Figures 1b and
S1). Following the trypsin digestion, disks were separated into three
groups (Figure 2a). The ﬁrst group was directly used for nano-
mechanical tests, discussed in detail in the next section. The second
group was further treated with 10 μg/mL human recombinant matrix
metalloprotease-13 (rhMMP-13, gift from Ivan Otterness, Pﬁzer) for
24 h in 37 °C water bath. MMP-13, or collagenase-3, cleaves type II
collagen molecules and is highly overexpressed in osteoarthritis,
resulting in degradation of collagen ﬁbrils.22 The third group was
further treated with 0.1 mg/mL bacterial collagenase (BC) from
Clostridium histolyticum (Worthington Biochemical Corporation,
Lakewood, NJ) for 10 min at 37 °C to induce more severe partial
degradation of the collagen network. The BC was added to PBS with
Ca2+ for activation and preheated in 37 °C water bath for 30 min
before the treatment.23
Figure 1. (a) Schematic of the structure and major molecular
constituents of the articular cartilage extracellular matrix (ECM),
including the type II/IX/XI ﬁbrillar collagen network, aggrecan
moiety, and hyaluronan that aggrecan binds to,7 which is stabilized by
the link protein.8 The scale bar is an estimate based on the dimensions
of aggrecan and collagen ﬁbrils. Molecular density is reduced to
increase clarity. (b) Tapping mode atomic force microscopy (AFM)
amplitude image of air-dried, proteoglycan-depleted calf knee cartilage
surface, which displays the transversely isotropically aligned collagen
ﬁbrils and the nanoscale d-banding patterns (arrows). (c) Tapping
mode AFM height image of individual fetal epiphyseal aggrecan
monomer (adapted with permission from ref 27), illustrating the N-
and C-termini of the core protein, chondroitin sulfate glycosamino-
glycan (CS-GAG), and keratan sulfate (KS)-GAG side chains. (d)
Schematics of the dissacharide constituents of the CS-GAG
(chondroitin-4-sulfate GAG) and KS-GAG.3,4
Figure 2. (a) Flowchart of types of collagen networks specimens as a
result of diﬀerent enzymatic treatments and the types of aqueous
solutions for aggrecan−collagen adhesion test. (b) Schematics of
colloidal force spectroscopy using microspherical tips (end radius R ≈
2.5 μm) functionalized with hydroxyl-terminated self-assembled
monolayer (OH-SAM) and aggrecan. (c) Typical force vs depth
(F−D) curves measured via OH-SAM and aggrecan tips (PBS, [Ca2+]
= 0 mM, surface dwell time td = 30 s). Curves shown are from three
diﬀerent locations for each tip. (Inset) Deﬁnitions of the maximum
adhesion force, Fad, total adhesion energy, Ead, and maximum adhesion
interaction distance, Dad, for each F−D curve.
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Histology and Structural Characterization. Histology was
carried out on disks from untreated, trypsin-only treated, and disks
treated with both trypsin and BC to analyze the gross level
morphology. Aggrecan/proteoglycan and collagen were visualized
using Safranin-O and Masson’s Trichrome, respectively.24 To
characterize the collagen network structure, additional disks from all
three trypsin-treated groups were ﬁxed via the Ohtani’s procedure to
retain its three-dimensional architecture and subsequently imaged
using scanning electron microscopy (SEM).25,26 Brieﬂy, disks were
ﬁxed in 10% formalin for 1 day and then immersed in 10% NaOH for
6 days. Specimens were subsequently washed with Milli-Q ﬁltered
water for 1 day and then immersed in 1−2% tannic acid for 5 h. A
second one-day water rinse was followed by ascending alcohol series
dehydration and counterﬁxing in 1% OsO4 (Sigma-Aldrich, St. Louis,
MO) for 2 h. Specimens were then lyophilized (FreeZone Freeze-Dry
System, Labconco, Kansas City, MO) and Au−Pd sputter-coated (≈ 8
nm thickness; Quorum Technologies, Guelph, Ontario, Canada) prior
to imaging. These disks were then imaged via SEM (Helios 600 Dual
Beam FIB/SEM, FEI, Hillsboro, OR). The nanostructure of the
trypsin only treated collagen network was characterized via tapping
mode AFM imaging on overnight air-dried disks, using a Multimode
IIIA AFM (Veeco, Santa Barbara, CA) and Olympus AC240TS-2
rectangular Si cantilevers (nominal tip radius R < 10 nm, spring
constant k ∼ 2 N/m, Asylum Research, Santa Barbara, CA).
Colloidal Atomic Force Microscope Tip Preparation. Puriﬁed
fetal bovine epiphyseal A1A1D1D1 aggrecan, MW ≈ 3 MDa,27 was
chemically functionalized with thiol groups at the N-terminal, as
described previously.28 Gold-coated borosilicate colloidal AFM
spherical tips (end radius R ≈ 2.5 μm, nominal spring constant k =
0.58 N/m, Novascan, Ames, IA) were chemically end-attached with
aggrecan by immersion in 100 μL of 1 mg/mL thiol-functionalized
aggrecan solution in a humidity chamber for 48 h.16,29 The thiol-gold
bonding between aggrecan and the colloid resulted in an aggrecan
packing density of ≈50 mg/mL (one monomer per ≈25 nm × 25 nm
square),16,29,30 which is within the physiological range of aggrecan in
cartilage (20−80 mg/mL).31 As a control, identical colloidal probe tips
with the same speciﬁcations were functionalized with hydroxyl-
terminated self-assembled monolayer (OH-SAM) by immersion in 3
mM 11-mercaptoundecanol (HS(CH2)11OH, Sigma-Aldrich, St. Louis,
MO) ethanol solution for 24 h. With this neutral, hydrophilic, hard-
wall tip, the eﬀects of electrostatic repulsion, hydrophobicity, and
macromolecular entanglement are minimized. Results measured from
the OH-SAM tip can thus be used to elucidate the origins of the ionic
strength and [Ca2+] dependence of aggrecan−collagen adhesion. Both
the aggrecan and OH-SAM functionalized tips have been shown to
have surface roughness less than 5 nm (≪ than the tip radius of
curvature),29 suggesting that the surface roughness had negligible
impact on the outcomes.
Nanomechanical Experiments. Colloidal force spectroscopy was
performed using a 3D Molecular Force Probe (MFP-3D, Asylum
Research, Santa Barbara, CA) to quantify the adhesion between the
proteoglycan-removed cartilage disks with undamaged collagen
network and the aggrecan-functionalized tip. The experiment was
carried out on the disk surface away from the cutting edges in several
aqueous solutions (Figure 2a): (1) physiological-like solution of PBS
(IS = 0.15 M, pH ≈ 7.4), (2) 0.01−1.0 M NaCl solutions (pH ≈ 5.6),
and (3) 0.15 M IS NaCl + CaCl2 solutions with varying [Ca
2+] = 0−20
mM (pH ≈ 5.6). Within this pH range, the GAG chains of aggrecan
maintain constant negative charge density and compressive nano-
mechanical behaviors.28 The tip was programmed to indent into the
disk for a maximum depth d ≈ 500 nm at 0.5 μm/s indentation depth
rate and then to retract from the sample at the same rate after holding
at the constant depth for a given surface dwell time td (0−60 s). The
test was carried out in the indenter mode, in which the z-piezo
displacement was continuously adjusted to compensate for cantilever
bending and to maintain constant indentation rate and maximum
indentation depth. Additional control experiments were carried out on
the same disks using the hard-wall OH-SAM tips under the same
conditions (Figure 2b).
To quantify the aggrecan−collagen adhesion force and energy, we
calibrated the cantilever deﬂection sensitivity (nm/V) on a hard silica
surface in 1.0 M NaCl solution to minimize the electrostatic repulsion.
At this ionic strength, the aggrecan monolayer can be approximated as
incompressible at forces >40 nN, as shown in our previous aggrecan
compression studies using the same tips.29 The spring constant was
then determined via the thermal oscillation method.32 Proper
functionalization of aggrecan tips was veriﬁed on mica by conﬁrming
the >300 nm long-range repulsion at low IS (0.001 M) and its absence
at high IS (1.0 M).28,29 It is unlikely that this repulsion is due to
electrical double layer repulsion arising from surface charges, given the
interaction distance (>300 nm) is substantially greater than the Debye
length κ−1 ≈ 10 nm at IS = 0.001 M. The eﬀective tip−sample contact
point was determined by the Golden Section-based algorithm
described previously.33,34 The maximum adhesion force, Fad, and
total adhesion energy, Ead, were calculated on each of the indentation
force-depth (F−D) retract curves (Figure 2c). For each experimental
condition, the measurement was repeated for n ≥ 10 locations on each
of the disks from the joints of at least three diﬀerent calves. One
measurement was carried out at each location, except for the test of the
surface dwell time td dependence, where a total of nine repeats were
conducted at the same location, one repeat for each td from 0−60 s.
Statistical Analysis. To avoid the assumptions of data normal
distribution and homoscedasticity, nonparametric statistical tests (e.g.,
Mann−Whitney test, Kruskal−Wallis analysis of variance test, and
Friedman repeated-measure analysis of variance test) were performed
to examine the overall signiﬁcance of various test conditions, including
the surface dwell time td, ionic strength IS, [Ca
2+], and enzymatic
treatments of the collagen network. Mann−Whitney test was carried
out to compare the data between each pair of ionic strength, [Ca2+] or
enzymatic treatments. Data from diﬀerent calves under the same
experimental conditions were pooled, as no statistical diﬀerences in Fad
or Ead were found between collagen specimens from diﬀerent animals
via Mann−Whitney test (p > 0.05).
Figure 3. (a) Maximum adhesion force, Fad, and (b) the total adhesion energy, Ead, for the indentation of proteoglycan-depleted cartilage with OH-
SAM and aggrecan functionalized microspherical tips (R ≈ 2.5 μm) in 0.15 M PBS (mean ± SEM, n ≥ 50 locations from more than four cartilage
disks).
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■ RESULTS
When using both the OH-SAM and aggrecan tips to indent
onto the trypsin-treated (PG-depleted, collagen network only)
cartilage disks, we observed characteristic long-range force−
indentation depth curves at 500 nm indentation depth, td = 30 s
in PBS (Figure 2c). Increasing the surface dwell time td resulted
in signiﬁcant, nonlinear increase in both the maximum adhesion
force, Fad, and the total adhesion energy, Ead (Figure 3,
Friedman test, p < 0.001). In comparison, changing td had no
appreciable eﬀects on the maximum distance of the adhesion
interactions, Dad (Figure 2c). For the control experiment (OH-
SAM tip), Fad varied from 1.2 ± 0.1 to 5.3 ± 0.4 nN, and Ead
varied from 0.7 ± 0.1 to 4.2 ± 0.4 fJ, when changing td from 0
to 60 s, respectively. The aggrecan probe tip showed
signiﬁcantly lower Fad of 0.8 ± 0.1 nN at td = 0 s and 3.1 ±
0.2 nN at td = 60 s (Figure 3a, Friedman test, p < 0.01), and
similar adhesion energy, Ead = 1.3 ± 0.2 fJ at td = 0 s to 3.9 ±
0.3 fJ at td = 60 s (Figure 3b, Friedman test, p > 0.05).
At the same indentation depth (500 nm) and surface dwell
time (td = 30 s), increasing ionic strength (IS) from 0.01 to 1.0
M signiﬁcantly increased both Fad and Ead for the aggrecan tip
(Figure 4, Kruskal−Wallis test, p < 0.001), with the exception
that Ead, which was similar for 0.01 and 0.15 M IS (p > 0.05).
Similarly, at IS = 0.15 M, increasing [Ca2+] from 0 to 20 mM
also markedly increased Fad and Ead for the aggrecan tip (Figure
5, Kruskal−Wallis test, p < 0.001). In comparison, the eﬀects of
both IS and [Ca2+] are absent for the adhesion between
collagen (PG-depleted cartilage disk) and the hard wall, neutral,
hydrophilic OH-SAM tip (Figures 4 and 5, Kruskal−Wallis test,
p > 0.05).
Removal of proteoglycans by trypsin digestion revealed the
transversely isotropic collagen ﬁbril alignment in the 2D surface
plane of the cartilage surface (Figures 1b and 6).35 For the
trypsin-only treated collagen network, the ﬁbril diameter was
found to be 40.5 ± 4.7 nm (mean ± STD, n ≥ 100 ﬁbrils), with
a packing density of ≈50 ﬁbrils per μm2 area (Figure 6). At this
length scale, eﬀects of either MMP-13 or bacterial collagenase
treatments were not noticeable (Figure 6a,b). In addition, at the
tissue level, the more severe collagen digestion by 10 min in
bacterial collagenase introduced no changes in collagen
concentration or structure (Figure 7). We thus expected similar
results from the milder MMP-13 digestion. While we did not
observe any appreciable eﬀects via ﬁbril-level imaging (Figure
6) or tissue-level histology (Figure 7), severe damage, and
disassembly of the molecular level structure of the ﬁbrillar
collagen network were expected.36 For the less severe, more
physiological-like MMP-13 digestion, immunohistochemistry of
untreated and MMP-13 treated cartilage disks using mono-
clonal neo-epitope antibody 9A4 to reveal collagenase cleavage
of collagen showed that 24 h MMP-13 treatment introduced
partial degradation of the collagen network in the upper 30 μm
of the superﬁcial zone (Figure S2).37 As a result, the maximum
adhesion force, Fad, between aggrecan and collagen signiﬁcantly
increased by a factor of ≈2.5× for both MMP-13 and BC
treatments at the same indentation depth (≈500 nm) and td =
30 s in PBS (Figure 8a, Mann−Whitney test, p < 0.001). The
total adhesion energy, Ead, also increased substantially for both
treatments, where the BC treatment (≈3× increase) had even
greater eﬀects than the MMP-13 treatment (≈1.5× increase;
Figure 8b, Mann−Whitney test, p < 0.001).
Figure 4. (a) Maximum adhesion force, Fad, and (b) the total adhesion
energy, Ead, for the indentation of proteoglycan-depleted cartilage with
OH-SAM and aggrecan functionalized microspherical tips (R ≈ 2.5
μm) in NaCl solutions at diﬀerent ionic strengths, td = 30 s (mean ±
SEM, n ≥ 50 locations on more than four cartilage disks, *p < 0.001
via Mann−Whitney test).
Figure 5. (a) Maximum adhesion force, Fad, and (b) the total adhesion
energy, Ead, for the indentation of proteoglycan-depleted cartilage with
OH-SAM and aggrecan functionalized microspherical tips (R ≈ 2.5
μm) in NaCl + CaCl2 solutions at [Cl
−] = 0.15 M and diﬀerent
[Ca2+], td = 30 s (mean ± SEM, n ≥ 50 locations from more than four
cartilage disks, *p < 0.001 via Mann−Whitney test).
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■ DISCUSSION
In this study, we investigated the origins and governing factors
of the aggrecan−collagen molecular adhesion. In particular, we
studied the roles of aggrecan GAG−GAG electrostatic
repulsion and Ca2+-mediated ion bridging eﬀects. These
interactions were studied in the context of the cartilage
extracellular matrix environments to elucidate their contribu-
tions to cartilage tissue assembly and biomechanical properties.
Furthermore, using partially digested collagen networks, we
explored how osteoarthritis-relevant degradation alters the
aggrecan−collagen molecular interactions, which in turn, aﬀects
cartilage tissue properties at the early stages of OA, when OA-
induced matrix changes are indistinguishable via either
macroscopic or microscopic analyses.
Relevance to In Vivo Aggrecan−Collagen Adhesion.
On native cartilage surfaces, the ECM is dominated by
transversely aligned collagen ﬁbrils,35 hyaluronan, proteogly-
cans, and glycoproteins such as lubricin (proteoglycan 4 or
PRG4),38 covered by a physically adsorbed phospholipid
layer.39−41 Aggrecan concentration is much lower in the
superﬁcial zone compared to the middle and deep zones.31,42,43
In this study, 6 mm diameter bovine cartilage disks with intact
superﬁcial zone were treated with bovine trypsin to remove
proteoglycans and expose individual collagen ﬁbrils (Figures 1b
and S1). While explants diced into small pieces accentuate cell
apoptosis and matrix degradation,44 the large explants used here
minimize cell death and enable maintenance of normal matrix
metabolism;45,46 thus, native collagen architecture is retained
away from the cut edges of the disks. The presence of
nondegraded collagen is further supported by the absence of
collagenase cleavage sites in the superﬁcial zone, which can be
detected via immunohistochemistry (Figure S2).37
The ﬁbrillar collagen network is expected to be the major
constituent of the trypsin-treated disks, as the physically
adsorbed surface-active phospholipid layer39−41 is expected to
be removed via rinsing in PBS,47 and proteoglycans such as
aggrecan and lubricin were removed by trypsin digestion
(Figure 7). While some hyaluronan may remain on the surface,
recent studies on cartilage surface lubrication have shown that a
12 h incubation with trypsin likely removed most hyaluronan
constituents48 due to the loss of its anchorage with aggrecan7
and lubricin.49 In addition, given that the total hyaluronan
content in cartilage is small (<0.3% wet wt)50 and its
concentration on the surface is even lower than that in the
bulk,51 hyaluronan is expected to have minimal direct
contribution to cartilage mechanical behavior. Digestion by
hyaluronidase did not signiﬁcantly impact cartilage surface
roughness, modulus, or friction coeﬃcient, as measured by
AFM.52 We therefore expect the net adhesion to be dominated
by aggrecan−collagen interactions.
Molecular Origins of Aggrecan−Collagen Adhesion.
Increasing surface dwell time td allows longer equilibration
between the compressed aggrecan and collagen and, therefore,
increases the number of eﬀective molecular contacts. As a
result, both the maximum adhesion force, Fad, and the total
adhesion energy, Ead, signiﬁcantly increased with td (Figure 3).
The measured adhesion is expected to be a complex balance of
various attractive and repulsive molecular interaction mecha-
nisms, as in most biomacromolecular systems. The repulsive
mechanisms include electrostatic repulsion between the
Figure 6. (a) Scanning electron microscopy images of trypsin-treated cartilage disk surfaces, prepared via Ohtani’s procedure25 to retain its 3D
architecture, including trypsin only, trypsin + MMP-13, and trypsin + bacterial collagenase treated disks. (b) Box-and-whisker plot of the distribution
of collagen ﬁbril diameters measured for the three types of disks (n ≥ 100 ﬁbrils for each treatment).
Figure 7. Histology images of the cross sections of untreated
(normal), trypsin-treated, and trypsin + bacterial collagenase (BC)
treated cartilage disks, stained with Safranin-O (for aggrecan) and
Masson’s Trichrome (for collagen).
Figure 8. (a) Maximum adhesion force, Fad, and (b) the total adhesion
energy, Ead, for the indentation of proteoglycan-depleted cartilage with
aggrecan functionalized microspherical tips (R ≈ 2.5 μm) in PBS, td =
30 s. The disks were treated with 0.1 mg/mL trypsin only (intact
collagen network), trypsin + 10 μg/mL human recombinant matrix
metalloprotease-13 (MMP-13), and trypsin + 0.1 mg/mL Clostridium
histolyticum bacterial collagenase (BC; mean ± SEM, n ≥ 50 locations
from more than four cartilage disks, *p < 0.001 via Mann−Whitney
test).
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chondroitin sulfate (CS)-GAGs and the negatively charged
amino acids on collagen molecules, excluded volume eﬀects,
hydration, as well as conformational, translational, and
rotational entropic penalties. The attractive mechanisms
include van der Waals contacts, hydrophobicity, hydrogen
bonding, physical entanglements, and electrostatic attraction
between GAGs and the positively charged amino acids on
collagen. Hydrogen bonding can take place between the −OH,
−COOH, and −SO3− groups (pKa of GAG carboxyl is ≈3 in
aqueous solutions53) on aggrecan and collagen.
The cartilage ﬁbrillar collagen network is a type II/IX/XI
collagen heteropolymer.54,55 Type II collagen is the major
constituent (≈80−90% molar ratio, increase with age).55 Type
IX collagen molecules (≈1−10% molar ratio, decrease with
age) are attached on the ﬁbril surfaces and provide covalent
cross-links between type II and other type IX collagens.56 Type
XI collagen (≈ 3 − 10% molar ratio, decreasing with age) forms
the ﬁbril nucleation cores that allow self-assembly of type II
ﬁbrils.57,58 Aggrecan−collagen adhesion thus mainly takes place
between aggrecan and type II collagen ﬁbrils and, to a lesser
extent, between aggrecan and the triple helical domain of the
surface type IX collagen. Trypsin digestion using bovine
pancreatic trypsin has been shown not to aﬀect the type II/XI
collagen ﬁbril structure or the triple helical domains of the type
IX collagen.20,59,60 However, the positively charged, heparin-
binding NC4 domain and the CS-GAG attached on the NC3
domain of type IX collagen were most likely removed by
trypsin, as previously reported for full length recombinant
collagen IX.61 While removal of these domains could result in
underestimation of the aggrecan−collagen adhesion, we expect
this eﬀect to be minimal given the relative low concentration of
collagen IX.
Each type II collagen triple helix consists of three colIIαI
polypeptide chains. One calf colIIα1 molecule contains 1487
amino acids,62 including 995 hydrophobic, 211 hydrophilic
(neutral), 140 positively charged, and 141 negatively charged
amino acids (Figure S3).62 While each colIIα1 molecule is net
neutral at physiological pH, local positive and negative charges
could be present along the ﬁbrils. Interactions between
aggrecan and the triple helical region of type IX collagens
(with three diﬀerent polypeptide chains, colIXαI, colIXαII, and
colIXαIII) also contribute to the net adhesion, albeit to a much
lesser extent, due to its low concentration.55 For aggrecan, each
CS-GAG chain contains ≈40−50 disaccharide units, in which
both polar and nonpolar groups are present1,63 (Figure 1c,d).
Nonpolar patches along the aggrecan CS-GAGs and hydro-
phobic amino acids on collagen (e.g., 995 hydrophobic amino
acids on each colIIα1) can lead to hydrophobic interactions.64
At the maximum indentation force ≈40 nN, aggrecan is
compressed at ≈50% molecular strain.29 CS-GAGs can also
undergo conformational changes and form physical entangle-
ments with relatively stiﬀ collagen ﬁbrils. Given the
conﬁguration of aggrecan attachment onto the spherical tip
(Figure 2b), it is less likely that the shorter KS-GAG chains play
an important role in this measured adhesion. In addition, if
multivalent ions such as Ca2+ are present, additional charge
redistribution,65 and ion-bridging eﬀects66 will also contribute
to the net aggrecan−collagen adhesion. In this study, however,
like our previous aggrecan−aggrecan adhesion work,16 we were
unable to distinguish a single dominating molecular mechanism
due to the complexity of biological macromolecules, i.e.,
aggrecan and collagen. According to their molecular
composition and structure, we expect that all the proposed
mechanisms are synergistically involved in the net adhesion.
Eﬀects of Ionic Strength. Variations of Fad and Ead with
ionic strength (IS) provide insights into how electrostatic
interactions govern aggrecan−collagen adhesion in vivo.
Increasing IS eﬀectively shields the GAG−GAG electrostatic
repulsion and, consequently, alters the conformation and
compressibility of aggrecan monomers. Increasing IS from
0.01 M (Debye length κ−1 ≈ 3 nm) to physiological-like 0.15 M
(κ−1 ≈ 1 nm) did not completely screen the GAG−GAG
repulsion, given the intra- and inter-GAG charge distance is
≈1−2 nm within aggrecan.27 Aggrecan monomers partially
retain the long-range repulsive, more elongated conformation.
Increasing IS from 0.01 to 0.15 M thus has only marginal (Fad)
or nonsigniﬁcant (Ead) eﬀects on the aggrecan−collagen
adhesion (Figure 4). Further increase of IS to 1 M (κ−1 ≈
0.3 nm) completely shields the GAG−GAG electrostatic
repulsion, and aggrecan monomers behave similar to neutral
brush-like polymers.29,67 Removal of aggrecan electrostatic
repulsion signiﬁcantly increases both the deformability of
aggrecan and eﬀective aggrecan−collagen molecular contacts,
and therefore, aggrecan−collagen molecular adhesions (≈2× in
Fad, ≈1.5× in Ead compared to 0.15 M, Figure 4). Since the
collagen network is net neutral, changing ionic strength has
negligible eﬀects on the molecular deformability and surface
properties of the collagen ﬁbrillar network. From the F−D
loading curves (data not shown) measured by the OH-SAM
tips, we did not detect signiﬁcant IS dependence on the
indentation resistance, consistent with previous reports
showing that the collagen network nanostiﬀness is independent
of bath IS.68 Similarly, increasing IS from 0.01 to 1.0 M had no
signiﬁcant eﬀect on the either Fad or Ead between the OH-SAM
tip and the collagen network (Figure 4).
Eﬀects of Divalent Ca2+. When increasing [Ca2+] from 0
to 20 mM at 0.15 M IS, we observed an ≈3× increase in Fad
and an ≈1.5× increase in Ead of aggrecan−collagen adhesion
(Figure 5). The presence of divalent Ca2+ ions alters the free
counterion distribution65 and introduces ion bridging between
multiple negative charges.66 Previously, this redistribution eﬀect
on aggrecan compressibility was observed to saturate at [Ca2+]
≥ 2 mM.69 Thus, the monolithic increase in aggrecan−collagen
adhesion with [Ca2+] from 0 to 20 mM suggests the likely
dominant role of the ion bridging eﬀect.66 It is known that one
Ca2+ can bind electrostatically between two monovalent
negative charges on the GAG side chain70,71 and between the
GAG chain and the aggrecan core protein.72 It is also possible
that Ca2+ can bind between GAGs and the local negative
charges on collagen. Due to the local rigidity of the ﬁbrillar
collagen network, it is less likely for Ca2+ ions to simultaneously
act on multiple negative charges on colIIα1 molecules, as
demonstrated by the negligible [Ca2+] dependence measured
by the OH-SAM tip (Figure 5). The physiological concen-
tration of [Ca2+] is ≈2−4 mM,31 and within this range,
variations in Ca2+ concentration can strongly aﬀect the
aggrecan−collagen adhesion (Figure 5), as well as aggrecan−
aggrecan adhesion.16
Comparison to Molecular Adhesion of Other Carti-
lage Matrix Proteoglycans. At ≈500 nm indentation depth,
there are ≈1 × 104 aggrecan monomers and ≈340 collagen
ﬁbrils simultaneously in direct molecular contact underneath
the ≈7 μm2 contact area (tip radius R ≈ 2.5 μm). In PBS, the
average nonspeciﬁc binding force is thus ≈0.3 pN per aggrecan
monomer and ≈9 pN per collagen ﬁbril. However, since
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adhesion may occur within only a fraction of these molecules,
this is an estimate of the lower limit of the aggrecan−collagen
binding strength. This value is comparable to the estimated per
pair aggrecan−aggrecan binding strength (≈1 pN) between
two opposing end-attached aggrecan layers.16 Thus, in vivo,
aggrecan may have no strong preference in binding to adjacent
aggrecan monomers or collagen ﬁbrils, despite their drastically
dissimilar charged nature and molecular stiﬀness. These
nonspeciﬁc bindings are orders of magnitude weaker than the
binding strength measured on individual pairs of other cartilage
ECM proteoglycans via single molecule force spectroscopy,
such as hyaluronan/aggrecan G1 core protein (40 ± 11 pN),73
decorin/decorin (16.5 ± 5.1 pN),73 type IX collagen/biglycan
(≈15 pN),73 type I collagen/decorin (core protein; 54.5 ± 20
pN),74 and type I collagen/decorin (GAG side chain; 31.9 ±
12.4 pN).74 They are also much weaker than the adhesion
measured between individual pairs of aggrecan molecules
(≈150−250 pN).17 These diﬀerences can be mainly attributed
to two reasons. First, for each aggrecan−collagen pair, the
aggrecan−aggrecan and aggrecan−collagen intermolecular
interactions from the surrounding environment can aﬀect its
local binding interactions. Second, the maximum compressive
stresses applied on each molecule were lower than those
between the single molecular pairs in other studies. Those
experiments were measuring the upper limits of molecular
adhesions between each pair of single molecules, while our
experiment was designed to estimate the molecular interactions
in vivo by more closely simulating the physiological ionic
environment, loading conditions, molecular strains, and
molecular packing density.
Implications Regarding Cartilage Tissue Assembly
and Properties. In articular cartilage, aggrecan is entrapped in
the 3D randomly aligned collagen network with ≈30−50%
molecular strain at 20−80 mg/mL concentration.31 Cartilage
tissue mechanical function is determined by the hierarchy of
structure and collagen/aggrecan mechanical properties arising
from the nanoscale.2,68,75 In the present study that focuses on
the aggrecan−collagen adhesion, aggrecan monomers were
end-grafted at a packing density (≈50 mg/mL) within this
physiological concentration, and collagen ﬁbrils are transversely
randomly aligned on the cartilage surface (Figures 1b and 6).
At the maximum compressive force (≈40 nN), aggrecan
macromolecules on the tip were also at ≈50% molecular
strain.29 This experiment thus provided a two-dimensional
analog of the three-dimensional aggrecan−collagen interaction
in vivo. In both cases, it is the CS-GAG versus collagen
molecular contacts dominating the aggrecan−collagen inter-
actions, as the aggrecan core proteins are buried within the
densely packed CS-GAG side chains. Although previous studies
have suggested high binding aﬃnity of KS-GAGs to type II
collagen,9 our experiment did not investigate the KS-GAG and
collagen adhesion due to the aggrecan attachment conﬁguration
(Figure 2b). In addition, this experiment most likely excluded
the molecular interactions between aggrecan versus the
positively charged NC-4 domain and negatively charged CS-
GAG attached to the NC-3 domain of the type IX collagen.61
As discussed before, it is also likely that some residual
hyaluronan molecules may contribute to the net adhesion.
However, again, contributions of these interactions to the net
adhesion are believed to be minor given their low
concentrations compared to the type II collagen molecules
and CS-GAG side chains.
In articular cartilage, the magnitude of the aggrecan−collagen
adhesion per pair molecules is much weaker compared to other
speciﬁc molecular interactions that directly involve the ECM
matrix assembly. For example, interactions directly involved in
cartilage matrix assembly include the binding of aggrecan versus
hyaluronan at the G1 domain (facilitated by the link protein),7
COMP versus type II collagen,12 and ﬁbromodulin/decorin
versus collagen ﬁbrils.76 Aggrecan−collagen adhesion therefore
is not directly involved in regulating the cartilage matrix
assembly. However, given the abundance of aggrecan and
collagen in cartilage ECM, aggrecan−collagen adhesion could
work synergistically with the aggrecan−aggrecan self-adhesion16
as physical cross-links to aﬀect the local conformation and
deformability of aggrecan monomers, and in turn, nanoscale
charge distribution heterogeneity, aggrecan entropic elasticity
and eﬀective hydraulic permeability in the ECM. Upon external
loading, breaking of these physical cross-links can also provide
additional energy dissipative mechanisms to enhance the shock
absorption. We thus expect that these interactions play essential
roles in the organization and mechanical function of cartilage,
including electrostatic repulsion-driven elasticity, osmotic
swelling, and ﬂuid ﬂow-independent viscoelasticity, as well as
the ﬂuid ﬂow-induced poroelasticity.
Implications Regarding Osteoarthritis-Induced Carti-
lage Degradation. At early stage osteoarthritis, aggrecan is
the ﬁrst major constituent that undergoes fragmentation and
depletion,77,78 followed by the disruption of the collagen
network.79,80 In severe osteoarthritis, damage of both aggrecan
and collagen ﬁbrils take place simultaneously, which eventually
leads to the loss of cartilage.81 In order to provide molecular
insights into the progression of OA, we previously investigated
the OA-induced changes in local compressive and energy-
dissipative mechanical properties of cartilage tissue.34,43 Here,
we focused on one particular aspect of the OA-related cartilage
degradation, that is, the molecular adhesion between intact
aggrecan and partially degraded collagen ﬁbrils. Human
recombinant matrix metalloprotease-13 (MMP-13) is a typical
enzyme up-regulated in osteoarthritic cartilage, which contrib-
utes to the collagen ﬁbril degradation in vivo.82 A previous
immunohistochemistry study showed that 24 h MMP-13
digestion introduces partial deﬁbrillization of collagen within
the top ≈30 μm surface of cartilage (Figure S2),37 although
these changes are not visible at the microscale via SEM imaging
(Figure 6). As a result, we observed an ≈2.5× increase in Fad
and an ≈1.5× increase in Ead (Figure 8). MMP-13 cleaves the
colIIα1 molecule amino acid sequence at the locations of
PQG775−776LAG and LAG778−779QRG and results in disor-
ganized collagen ﬁbrils.22 This deﬁbrillization could increase the
eﬀective molecular surface contacts and deformability of type II
collagen molecules and may also expose the type XI collagen
molecules wrapped at the core of these ﬁbrils.54 All these eﬀects
can increase the eﬀective molecular contacts and, thus, the
aggrecan−collagen adhesion. This deviation from normal
aggrecan−collagen interactions in healthy cartilage contributes
to the changes in both cartilage mechanics and chondrocyte
responses. For example, an increase in aggrecan−collagen
association could alter the local deformability of aggrecan, and
in turn aﬀect the visco/poroelastic energy dissipation directly
linked to aggrecan/collagen, aggrecan/aggrecan, and aggrecan/
water molecular friction. In addition, altered aggrecan−collagen
molecular interactions upon partial degradation of collagen are
also expected to aﬀect speciﬁc interactions with other
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chondrocyte-binding growth factors or cytokines and, in turn,
lead to altered chondrocyte signaling.83
The C. histolyticum bacterial collagenase enzyme is not
directly related to physiological conditions. It cleaves the
collagen ﬁbrils at six locations at a much faster rate than MMP-
1336 and represents a model of more severely damaged collagen
networks. Under this scenario, we observed similar values of Fad
but much greater Ead (Figure 8), suggesting more severe
damage of collagen could further increase aggrecan−collagen
adhesion, deviating from the normal aggrecan−collagen
interactions. Interestingly, both histological and SEM studies
showed that even under this more severely damaged scenario
by C. histolyticum, negligible diﬀerences were observed between
the undamaged (trypsin-only treated cartilage disk) and
partially damaged collagen network at the tissue and ﬁbril
levels (Figures 6 and 7). This is because, at this early stage of
OA-like degradation, these changes take place at the length
scales beyond the resolution of these techniques. This
observation thus also indicates that severe OA-induced cartilage
degradation may take place at a stage much earlier than the
level at which conventional techniques like histology or
radiology are able to detect (Figure 7). Interestingly, previous
studies have shown that whereas healthy to grade 3
osteoarthritic human cartilage exhibited no signiﬁcant diﬀer-
ences in eﬀective indentation modulus using a microspherical
tip, their moduli decreased for a factor ≈95% if measured by a
softer, nanosized pyramidal tip.75 Our observation further
elucidates the importance and sensitivity of molecular level
phenomena taking place at the nanometer scale to osteo-
arthritic degradation.
■ CONCLUSIONS
In this study, we quantiﬁed the molecular adhesion between the
two major cartilage extracellular matrix constituents, that is,
aggrecan and the type II/IX/XI ﬁbrillar collagen network, in
physiological-like aqueous solutions. This aggrecan−collagen
adhesion is nonspeciﬁc and governed by both GAG−GAG
electrostatic repulsion and Ca2+-induced ion bridging eﬀects in
vivo. Aggrecan−collagen adhesion, similar to aggrecan−
aggrecan self-adhesion, could be an important factor that
determines the local assembly and molecular deformability of
the cartilage matrix. By introducing osteoarthritis-like degrada-
tion via MMP-13, we found partial disruption of collagen
structure leads to signiﬁcant increase in aggrecan−collagen
adhesion. This study provides further molecular-level insights
into the assembly and degradation of cartilage tissue, as well as
disease induced tissue degradation. Information obtained here
contributes to the molecular-level knowledge of cartilage and
osteoarthritic degradation, which can be used for designing and
optimizing the early stage OA-diagnostics tools and tissue-
engineering strategies for cartilage repair.
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